Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
Andrzej PilcAgata MachaczkaPaweł KawalecJodi L SmithJeffrey M WitkinPublished in: Expert opinion on drug discovery (2022)
Preclinical and clinical data have accumulated to predict a next generation of antidepressant medicines. In contrast to the current standard of care antidepressant drugs, these compounds differ in that they demonstrate rapid activity, often after a single dose, and effects that outlive their presence in brain. These compounds also can provide efficacy for treatment-resistant depressed patients. The mechanism of action of these compounds suggests a strong glutamatergic component that involves the facilitation of AMPA receptor function. Antagonism of mGlu2/3 receptors is also relevant to the antidepressant pharmacology of this new class of drugs. Based upon the ongoing efforts to develop these new-age antidepressants, new drug approvals are predicted in the near future.
Keyphrases
- major depressive disorder
- drug discovery
- bipolar disorder
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- magnetic resonance
- palliative care
- chronic kidney disease
- emergency department
- drug induced
- electronic health record
- multiple sclerosis
- prognostic factors
- big data
- mesenchymal stem cells
- bone marrow
- artificial intelligence
- computed tomography
- cell therapy
- brain injury
- chronic pain
- health insurance
- quantum dots
- subarachnoid hemorrhage